This study suggests that men residing in counties with higher PSA screening prevalence prior to diagnosis had lower all-cause and prostate cancer-specific mortality; associations varied by sociodemographic and geographic factors, suggesting that targeted screening and linkage to treatment could improve prostate cancer survival. Here, KLK3 is linked to prostate carcinoma.